Literature DB >> 19404774

Childhood predictive genetic testing for Li-Fraumeni syndrome.

D G Evans1, P Lunt, T Clancy, R Eeles.   

Abstract

Presymptomatic genetic testing in childhood for adult onset conditions is generally discouraged as it does not directly benefit the child and removes their autonomy. In certain cancer prone conditions such as Familial Adenomatous Polyposis and Von Hippel Lindau disease there are risks of disease in childhood and benefit to children not inheriting a mutation in being able to forego unpleasant screening tests. Li-Fraumeni syndrome caused by constitutional TP53 mutations there are also implications in childhood with a risk of around 20% of a childhood malignancy. However, as yet no evidence based surveillance programme has been identified. We describe our experience of childhood testing for four children in two Li-Fraumeni families caused by TP53 mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19404774     DOI: 10.1007/s10689-009-9245-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  28 in total

1.  Uptake of genetic testing for cancer predisposition.

Authors:  D G Evans; E R Maher; R Macleod; D R Davies; D Craufurd
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

2.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Authors:  F P Li; J F Fraumeni
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

3.  Cancer in the families of children with soft tissue sarcoma.

Authors:  J M Birch; A L Hartley; V Blair; A M Kelsey; M Harris; M D Teare; P H Jones
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

4.  A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer.

Authors:  F Lalloo; A Baildam; A Brain; P Hopwood; D G Evans; A Howell
Journal:  Eur J Surg Oncol       Date:  2000-11       Impact factor: 4.424

Review 5.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Authors:  J M Birch; V Blair; A M Kelsey; D G Evans; M Harris; K J Tricker; J M Varley
Journal:  Oncogene       Date:  1998-09-03       Impact factor: 9.867

7.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

8.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Authors:  Magali Olivier; David E Goldgar; Nayanta Sodha; Hiroko Ohgaki; Paul Kleihues; Pierre Hainaut; Rosalind A Eeles
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

9.  Evaluation of a decision aid for families considering p53 genetic counseling and testing.

Authors:  Susan K Peterson; Rebecca D Pentz; Amie M Blanco; Patricia A Ward; Beatty G Watts; Salma K Marani; Leslie Colvin James; Louise C Strong
Journal:  Genet Med       Date:  2006-04       Impact factor: 8.822

10.  Excess risk of breast cancer in the mothers of children with soft tissue sarcomas.

Authors:  J M Birch; A L Hartley; H B Marsden; M Harris; R Swindell
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

View more
  9 in total

1.  Predictive genetic testing in children: constitutional mismatch repair deficiency cancer predisposing syndrome.

Authors:  Zandrè Bruwer; Ursula Algar; Alvera Vorster; Karen Fieggen; Alan Davidson; Paul Goldberg; Helen Wainwright; Rajkumar Ramesar
Journal:  J Genet Couns       Date:  2013-10-15       Impact factor: 2.537

2.  Ethical issues in presymptomatic genetic testing for minors: a dilemma in Li-Fraumeni syndrome.

Authors:  Brice Fresneau; Laurence Brugières; Olivier Caron; Grégoire Moutel
Journal:  J Genet Couns       Date:  2012-12-12       Impact factor: 2.537

3.  Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome.

Authors:  June A Peters; Regina Kenen; Renee Bremer; Shannon Givens; Sharon A Savage; Phuong L Mai
Journal:  J Genet Couns       Date:  2015-11-30       Impact factor: 2.537

Review 4.  Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician.

Authors:  Alexis Teplick; Megan Kowalski; Jaclyn A Biegel; Kim E Nichols
Journal:  Eur J Pediatr       Date:  2011-01-06       Impact factor: 3.183

5.  Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

Authors:  Kate A McBride; Mandy L Ballinger; Timothy E Schlub; Mary-Anne Young; Martin H N Tattersall; Judy Kirk; Ros Eeles; Emma Killick; Leslie G Walker; Sue Shanley; David M Thomas; Gillian Mitchell
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

6.  Li-fraumeni syndrome.

Authors:  David Malkin
Journal:  Genes Cancer       Date:  2011-04

Review 7.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

8.  Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li-Fraumeni syndrome.

Authors:  Anna Etzold; Julia C Schröder; Oliver Bartsch; Ulrich Zechner; Danuta Galetzka
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

9.  High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort.

Authors:  Gillian Mitchell; Mandy L Ballinger; Stephen Wong; Chelsee Hewitt; Paul James; Mary-Anne Young; Arcadi Cipponi; Tiffany Pang; David L Goode; Alex Dobrovic; David M Thomas
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.